Whereas traditional phase II cancer trials are usually single-arm, with tumor response as endpoint, and phase III trials are randomized and incorporate interim analyses with progressionfree survival or other failure time as endpoint, this paper proposes a new approach that seamlessly expands a randomized phase II study of response rate into a randomized phase III study of time to failure. This approach is based on advances in group sequential designs and joint modeling of the response rate and time to event. The joint modeling is reflected in the primary and secondary objectives of the trial, and the sequential design allows the trial to adapt to increase in information on response and survival patterns during the course of the trial, and to stop early either for conclusive evidence on efficacy of the experimental treatment, 1 or for the futility in continuing the trial to demonstrate it, based on the data collected so far.
INTRODUCTION
While randomized phase II studies are commonly conducted in other therapeutic areas, in oncology the majority of phase II studies leading to phase III studies are single-arm, as noted by El-Maraghi and Eisenhauer [1] and Chan et al. [2] , and they typically measure the efficacy of a treatment by an early or short-term binary response, such as complete or partial tumor response or whether the disease has progressed at a predetermined time after treatment is initiated. If the results meet or exceed the efficacy target, the treatment is declared worthy of further investigation; otherwise, further development is stopped. The most commonly used phase II designs are Simon's [3] single-arm two-stage designs, which allow early stopping of the trial if the treatment has not shown benefit. These two-stage designs, testing the null hypothesis H 0 : p ≤ p 0 with significance level α and power 1 − β at a given alternative p 1 , choose the first-stage sample size n 1 = m, the second-stage sample size n 2 = M − m, and the acceptance thresholds of H 0 at the end of the first and second stages to minimize the expected sample size at p 0 . Variations of this two-stage design have also been introduced, e.g., by Jung, Lee and Kim [4] and Banerjee and Tsiatis [5] .
Whether the new treatment is declared promising in a single-arm phase II trial, however, depends strongly on the prespecified p 0 and p 1 . As noted in Vickers et al. [6] , uncertainty in the choice of p 0 and p 1 can increase the likelihood that (a) a treatment with no viable positive treatment effect proceeds to phase III, for example, if p 0 is chosen artificially small to inflate the appearance of a positive treatment effect when one exists; or (b) a treatment with positive treatment effect is prematurely abandoned at phase II, for example, if p 1 is chosen optimistically large. In their systematic review of phase II trials published in the Journal of Clinical Oncology or Cancer in the 3 years to June 2005, Vickers et al. [6] identified 70 of the 134 trials that were deemed to require historical data for design. Nearly half (32) of these studies did not cite the source for the control rate p 0 . No study accounted for sampling error in the control estimate or possible case mix difference between the phase II sample and the historical cohort. Trials that failed to cite prior data appropriately were significantly more likely to declare an agent to be active (82% versus 33%; p=0.005). They concluded that "more appropriate use of historical data in phase II design will improve both the sensitivity and specificity of phase II for eventual phase III success, avoiding both unnecessary definitive trials of ineffective agents and early termination of effective drugs for lack of apparent benefit."
It is well known that the success rate of phase III cancer clinical trials is low [7] . This indicates that preliminary data at end of phase II studies are inadequate for determining whether to launch phase III trials and how to design them.
To circumvent the problem of choosing p 0 , randomized phase II designs have been advocated by Vickers et al. [6] , Ratain and Sargent [8] , and Rubinstein, Crowley and Ivy [9] . In particular, it is argued that randomized phase II trials are needed before proceeding to phase III trials when (a) there is not a good historical control rate, due to either incomparable controls (bias), few control patients (large variance of the control rate estimate) or outcome that is not "antitumor activity"; (b) when the goal is to select one from several candidate treatments or several doses for use in phase III. However, while randomized phase II studies are commonly conducted in other therapeutic areas, few phase II cancer studies are randomized with internal controls. The major barriers to randomization include that randomized designs typically require a much larger sample size than single-arm designs and that there are multiple research protocols competing for a limited patient population. Being able to include the phase 4 II study as an internal pilot for the confirmatory phase III trial may be the only feasible way for a randomized phase II cancer trial of such sample size and scope to be conducted.
In Section 2 we review two approaches to designing randomized phase II and phase II-III cancer trials that have been proposed in the past decade. One approach, which is limited to phase II, is frequentist and uses sequential generalized likelihood ratio (GLR) statistics to test differences in tumor response between two treatments. The other is Bayesian and uses a parametric mixture model that connects the tumor response endpoint in phase II to the survival endpoint in phase III in a Bayesian framework. In Section 3 we combine the idea of joint modeling of response and survival with that underlying group sequential GLR tests to develop a seamless phase II-III design that performs confirmatory testing by using commonly used likelihood ratio statistics for sample proportions and partial likelihood ratio statistics for censored survival data. Section 4 describes a prostate cancer study that has motivated the proposed design, gives a simulation study of its performance and provides the implementation details. Further discussion of the design and some concluding remarks are given in Section 5.
BIVARIATE ENDPOINTS OF TUMOR RESPONSE AND SURVIVAL

Randomized phase II trial as an internal pilot to test response rates
In standard clinical trial designs, the sample size is determined by the power at a given alternative, and an obvious method to determine a realistic alternative at which sample size calculation can be based is to carry out a preliminary pilot study. Noting that the results from a small pilot study are often difficult to interpret and apply, Wittes and Brittain [10] proposed to use an adaptive design, whose first stage serves as an internal pilot from which 5 the overall sample size of the study can be estimated. Bartroff and Lai [11, Sect. 3.2] have recently refined this idea to improve the two-stage randomized designs of Thall, Simon and Ellenberg [12] that extended Simon's two-stage designs for single-arm trials. Ellenberg and Eisenberger [13] pointed out the dilemma that although most clinical investigators are aware of the "unreliability of data" obtained in small single-arm phase II cancer trials, they cannot commit the resources needed for "comparative controlled trials, or phase III trials" that require much larger sample sizes until the new treatment has some promising results. Following Ellenberg and Eisenberger [13] , Bartroff and Lai [11] focus on tumor response as the primary endpoint so that phase II-III designs for this endpoint can be embedded into group sequential designs, with the first group representing the phase II component. In particular, the design proposed by Thall, Simon and Ellenberg [12] is basically a group sequential design with two groups that correspond to the two stages of the design. Instead of a conventional group sequential design, Bartroff and Lai [11] use an adaptive design which allows stopping early for efficacy, in addition to futility, in phase II as an internal pilot, and which also adaptively chooses the next group size based on the observed data. Despite the data-dependent sample size and the inherent complexity of the adaptive design, the usual GLR statistics can still be used to test for differences in the response rates of the two treatments, as the Markov property can be used to compute error probabilities in group sequential or adaptive designs.
Implementation details are given in Section 4.2.
Phase II-III designs with survival endpoint for phase III
Although tumor response is an unequivocally important treatment outcome, the clinically definitive endpoint in phase III cancer trials is usually time to event, such as time to death or 6 time to progression. The go/no-go decision to phase III is typically based on tumor response because the clinical time-to-failure endpoints in phase III are often of long latency, such as time to bone metastasis in prostate cancer studies. These failure-time data, which are collected as censored data and analyzed as a secondary endpoint in phase II trials, can be used for planning the subsequent phase III trial. Furthermore, because of the long latency of the clinical failure-time endpoints, the patients treated in a randomized phase II trial carry the most mature definitive outcomes if they are also followed in the phase III trial. Seamless phase II-III trials with bivariate endpoints consisting of tumor response and time to event are an attractive idea, but up to now only Bayesian statistical methodologies, introduced by Inoue, Thall and Berry [14] and Huang et al. [15] for their design and analysis, have been developed.
A Bayesian model connecting response and survival
The aforementioned Bayesian approach is based on a parametric mixture model that relates survival to response. Let Z i denote the treatment indicator (0=control, 1=experimental), T i denote survival time, and Y i denote the binary response for patient i. Assume that the responses Y i are independent Bernoulli variables and the survival time T i given Y i follows an exponential distribution, denoted Exp(λ) in which 1/λ is the mean:
Then the conditional distribution of T i given Z i is a mixture of exponentials:
The parametric relationship of response Y on survival T assumed by (1) and (2) Let Y denote the response and Z denote the treatment indicator, taking the value 0 or 1.
Consider the proportional hazards model
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The Inoue-Thall-Berry exponential model is a special case of (4), with λ 0 (·) being the constant hazard rate of an exponential distribution. Let π 0 = pr(Y = 1 | control) and π 1 = pr(Y = 1 | treatment). Let a = e α , b = e β and c = e γ , and let S be the survival distribution and f be the density function associated with the hazard function λ 0 so that λ 0 = f /S. From (4), it follows that the survival distribution of T is
for the control group (Z = 0),
for the treatment group (Z = 1).
We note that the coefficients β, γ in (4) 
as will be explained in the Appendix. In practice, graphical plots of the estimated survival curves are examined in order to interpret a finding of statistical significance of any summary of the observed benefit of treatment.
The two survival curves start at time 0 with the common value 1 and then grow apart if treatment is indeed beneficial, and eventually narrow in their difference and may even cross each other, with both curves approaching 0 if time is long enough. In view of this pattern for the survival difference
a of the control from the treatment group, (6) provides a simple and yet effective measure since (0) = 0 and A commonly adopted premise in the sequenced experiments to develop and test targeted therapies of cancer is that the treatment's effectiveness on an early endpoint such as tumor response would translate into long-term clinical benefit associated with a survival endpoint such as progression-free or overall survival, and conversely, that failure to improve that early endpoint would translate into lack of definitive clinical benefit. This explains why the go/no go decision to phase III made in a conventional phase II cancer trial is based on the response endpoint. Under this premise, the complement of the set of parameter values defining an efficacious treatment leads to the null hypothesis
3.2. Time-sequential partial likelihood ratio and modified Haybittle-Peto tests of H 0
Let t * denote the scheduled end of the clinical trial and 0 < t 1 < · · · < t k−1 denote the calendar times of interim analyses, and let t k = t * . The trial can stop prior to t * if significant differences between the treatment and control groups are found in an interim analysis. Suppose n patients enter the trial and are randomized to either the experimental or the standard treatment upon entry. Since they do not enter the trial at the same time, there are two time scales to be considered, namely, calendar time t as measured from the time the study starts and age time s as measured for each patient from the time the patient enters the study. The data at calendar time t, therefore, consists of
for the ith subject, where η i is the subject's entry time and ξ i is the subject's withdrawal time.
In (9), T i denotes the age time of ith subject, which is subject to two sources of censoring.
One is "administrative censoring", represented by (t − η i ) + , which is the duration between the subject's entry time η i and the calendar time t of interim analysis. The other is censoring due to withdrawal from the study at time ξ i , which may be infinite.
Consider the PH model (4). Let
in which R i (t) = {j : T j (t) ≥ T i (t)} is the "risk set" consisting of subjects still "at risk" (i.e., not having failed nor been censored) at calendar time t. The maximum partial likelihood estimator (π t ,θ t ) of (π, θ) can be computed by maximizing (10) to obtainπ t and maximizing (11) to obtainθ t .
The commonly used logrank statistic to test the null hypothesis that the hazard ratio of treatment to control, which is assumed to be time-invariant, is at least 1 considers only the T i and ignores the Y i . Thall [16, Sect. 6] notes that "the rationale for using a phase 2 trial based on an early response indicator Y to decide whether to proceed to a phase 3 trial based on T is that the occurrence of response is likely to increase the value of T , that is, T increases stochastically with Y ." Ignoring Y not only loses important information but also "ignore(s) the fact that the unconditional distribution of T is the mixture" of distributions for responders and non-responders, as pointed by Thall [16] . The Bayesian approach relies on the assumed parametric (i.e., exponential) survival model to deal with the mixing. Our approach returns to the root of the logrank test, i.e., the proportional hazards model that is intrinsically related to logistic regression, and modifies it by including the response indicator Y i as a covariate in (4).
As in the Bayesian approach, we consider the bivariate endpoint (Y i , T i ). However, because of the different information flow rates for Y i and T i , we use a group sequential design that bears some resemblance to the conventional demarcation of Y i as a phase II endpoint and T i as a phase III endpoint, as described below. In contrast, the Bayesian approach uses the posterior distribution of the difference in mean lifetime to combine the information from Y i and T i .
Because the survival endpoint involves a relatively long study duration, periodic reviews of the data are mandatory, at least for safety monitoring. Therefore we use a group sequential 14 instead of an adaptive design; see Jennison and Turnbull [17] who have shown that group sequential tests with suitably chosen group sizes can be nearly as efficient as their optimal adaptive counterparts that are considerably more complicated.
The bivariate endpoint is incorporated in the null hypothesis (7 
At each interim analysis, there is also a go/no-go decision on whether the trial should be stopped for futility. Thus, the trial can stop early not only to accept the alternative hypothesis in favor of the experimental treatment, but also to accept the null hypothesis H 0 .
To test H R 0 , we use the group sequential GLR tests introduced by Lai and Shih [18] , who call these tests "modified Haybittle-Peto tests" and have established their asymptotic optimality. Let
where l
t (π) is defined in (10) andπ t is the maximum likelihood estimator of π at calendar time t. Whereas Λ
(1) t is the GLR statistic for testing π 0 = π 1 , Λ
t,δ is the GLR statistic for testing the alternative hypothesis π 1 = π 0 +δ, with δ > 0 chosen to denote clinically significant alternatives, which will be used to guide futility stopping for the response endpoint. The stopping region of the group sequential GLR test of H R 0 is the following:
π t,0 <π t,1 , and Λ
(1)
Similarly, for η > 0, define
We can extend the modified Haybittle-Peto tests of Lai and Shih [18] and Gu and Lai [19] 
Note that k 0 is fixed at the design stage and t k 0 represents the calendar time of the first interim analysis of the phase III trial. During the execution of the trial, however, phase III testing is suspended at the jth analysis (
has not yet occurred.
In addition, the trial can stop early for futility to accept H 0 at calendar time t = t j (j < k) if π t,1 <π t,0 + δ and Λ
or d(π t , eα t , eβ t , eγ t ) < η and Λ
t,η ≥b S .
If H S 0 is not rejected and futility stopping has not occurred at t = t k−1 , reject H Since the endpoint for the combination therapy is actually bivariate, consisting of the PSA response and time to bone metastasis, the maximum sample size for testing this bivariate endpoint should be formulated in terms of a combined phase II and III trial, especially if the combined trial follows those patients in phase II through phase III. Based on the results of Smith et al. [22] , the 2-year bone metastasis rate in this patient population was anticipated to be 50%. Taking a 10% reduction (from 50% to 40%) in bone metastasis to be a clinically meaningful alternative hypothesis would require 368 events of bone metastasis for a one-sided 5% level logrank test to have 90% power at this alternative. Assuming 4 years of accrual with accrual rate 80, 120, 160 and 160, and 3 years of follow-up, this 7-year study would provide 385 events of bone metastasis, yielding 91% power.
In view of the uncertainties in the preceding guesses of the bivariate endpoint of the combination therapy relative to the standard-of-care therapy and the feasibility of the overall study, the clinical investigators recognized the need for innovative clinical trial designs. Subsequent research led to the following phase II-III design, which they found particularly attractive.
Using the notation of the preceding section, the trial has maximum duration t * = 7 (years) and three interim analyses are planned at t j = 1, 3, 5 years. The first analysis involves only a single center and 80 patients randomized to the two treatments, which corresponds to the randomized phase II trial to test PSA response that was originally planned. Embedding it in a group sequential phase II-III design has the advantage that one does not have to arrive at a definitive conclusion on response (i.e., whether the combination therapy is significantly better than the standard therapy), using the somewhat questionable sample size of 80 patients, for the study to continue. If the results show enough promise to attract additional funding and centers, the study can continue even when a statistically significant improvement in response has not been demonstrated. Another attractive feature of the modified Haybittle-Peto design is its statistically efficient provision for early stopping due to futility, analogous to the go/nogo provision in the widely used Simon's two-stage designs for single-arm phase II trials; see [11] , [18] .
Implementation details
Since H 0 is the disjoint union of H 
where α is the prescribed type I error probability. In particular, letting n t denote the number of subjects who have response data at time t, [18] uses the fact that the signed-root likelihood ratio statistics {sign(π 1 −π 0 )}(2n t Λ
t ) 1/2 have asymptotically independent increments and are asymptotically normal with mean 0 and variance n t under π 0 = π 1 . Therefore the probability in (19) can be computed by using recursive numerical integration [23] .
By using the theory of time-sequential partial likelihood ratio statistics ([24, Sect. V.5], [25] ), it can be shown that analogous to {sign(π 1 −π 0 )}(2n t Λ
t ) 1/2 is asymptotically N (0, Γ t ), with independent increments, under
where Γ t is determined from the log partial likelihood function (11) 
The type I error probability on H S 0 can be maintained by choosing the thresholds b S and c S such that pr d=0 {d(π t j , eαwe assume a random walk approximation to the signed-root likelihood (or partial likelihood) ratio statistics, with
where 0 < ε < 1 represents the fraction of type I error spent during the interim analyses prior to the prescheduled termination date t * of the trial. Note that j i=1 z i is the signed-root likelihood ratio statistic for testing that the mean of z i (with known variance 1) is 0 in the normal case. We recommend choosing ε between 1/3 and 1/2, as in [18] , and use ε = 1/3 in the simulation studies in the next section. The determination of c R or c S for the final analysis at t k , however, uses the actual n t j or Γ t j to evaluate the probability (19) or (22) .
Similarly, for a given type II error probabilityα, the futility boundariesb R andb S for early stopping can be determined by using the fact that {sign(π 1 −π 0 − δ)}(2n t Λ
approximately a normal random walk with mean 0 and variance n t under π 1 − π 0 = δ, and
is approximately a normal random walk with mean 0 and varianceΓ t under d(π t , e α , e β , e γ ) = η, whereΓ t is the same as Γ t but evaluated at the constrained maximum partial likelihood estimate under the constraint d(π t , e α , e β , e γ ) = η.
As in the preceding paragraph,b R andb S can be chosen at the design stage by assuming k − 1 (or k −k 0 ) standard normal increments z i in the random walk approximations to the boundary crossing probabilities. A software package to design and analyze the proposed phase II-III trial has been developed using R and is available at the website http://med.stanford.edu/biostatistics/ClinicalTrialMethodology.html
Simulation study of proposed test
Motivated by application in Section 4.1, we consider a maximum-duration trial with four years of accrual and additional 3 years of follow-up, with 80, 120, 160 and 160 patients entering the study uniformly within years 1, 2, 3, and 4, respectively. Response and survival data are generated according to (1) and (4) 
which assumes a PH model for the distribution of T given Z, to define the following analog of (15):
whereβ t = arg max l Table 1 gives the type I error probabilities pr(RS) and expected study duration E(T ) for 23 these three designs. Each result is based on 2000 simulations. Besides pr(RS), the table also
gives the probability pr(R) of rejecting H R 0 , and the probability pr(R 1 ) of rejecting H R 0 in the first interim analysis for the phase II-III design. Table 1 shows that the phase II-III design maintains the nominal type I error probability 0.05 for the parameter vectors considered.
When the true response rate of the control group is 0.6 instead of the assumed rate 0.3 (cases F and G), the phase II 1 & III design has over 90% probability of falsely claiming improvement in response, because the single-arm Simon's two-stage design for phase II 1 assumes π 0 to be 0.3 (see Section 4.1) and therefore satisfies the probability constraint on incorrectly rejecting INSERT TABLE 1 AND FIGURE 1 ABOUT HERE Table 2 gives the power and expected study duration for the three designs under various parameter configurations that have a common d(π, ξ) value of 0.25. When the true response rates are equal to the assumed values (cases 1-6), the proposed phase II-III design generally has higher or comparable power than the conventional designs and somewhat longer study duration. When the improvement in response is smaller than the assumed value (cases 7-8), is estimable in the presence of censoring to compare the survival curves. Third, the Bayesian designs do not stop early due to futility in the binary response Y . Under the premise described in Section 2.2, that no effect on Y implies no effect on survival, considering futility stopping on the binary response Y yields much shorter trial durations under the response null. Thus, to compare our design to the Bayesian design under circumstances that favor the latter, we must depart from the central premise of our method, and turn off futility stopping on Y .
To turn off futility stopping on Y , we consider instead of (7) the more restrictive null hypothesis
Note that H 0 is the same as H we can again use the stopping criteria (16) and (18), but not (17) , to test H 0 . We call this modified version of the design in Section 3.2 the "frequentist" counterpart of the Bayesian design of Huang et al. [15] . Unlike the phase II-III design in Section 3.2, these two designs do not actually have a phase II component for testing the effect of treatment on the binary response. Strictly speaking, it is a phase III trial on the survival outcome which involves the response rates via the parametric model (3) or the more general semiparametric model (4).
Comparison of frequentist operating characteristics between the methods is complicated by
this difference in what it means for one treatment to be "better than" another. However, we can still compare our design with the Bayesian design when both functionals in the preceding paragraph identify the same treatment as the better one. We can then compare the designs on three figures of merit: the probability pr(S) of selecting the experimental treatment over the control, the expected study duration E(T ), and the expected number of study subjects 26 E(N ). In particular, assuming exponential baseline survival, we perform the comparison for cases A, B, C, D, F, G in Table 1 and cases 1-9 in Table 2 . Table 3 gives the values of pr(S), E(T ) and E(N ) in these cases, for the Bayesian phase II-III design of Huang et al. [15] . Table 3 . Table 3 shows that under the null cases (cases A, B, C, D, F, G), the Bayesian ER and AR designs have approximately 0.05 probability of selecting the experimental treatment over the the control except for case D, but both designs have longer expected study durations and larger expected sample sizes than the frequentist counterpart. As expected, the contrast is even more marked in the comparison to the proposed phase II-III design in Section 3.2 (Table   1) , which takes advantage of futility stopping on Y . Under the alternative cases (cases 1-9), the Bayesian ER and AR designs have smaller expected sample sizes and shorter expected durations than the frequentist counterpart, but except for cases 4-7, they have have lower power than the frequentist counterpart whose power is over 85% in all the alternative cases.
INSERT TABLE 3 ABOUT HERE
Instead of using the same exponential baseline distribution as in Tables 1, 2, and 3, Table   27 4 provides parallel results when the baseline distribution is Weibull with hazard function λ 0 (t) = 0.45t 0.8 . Under the null cases, the Bayesian AR design fails to control the type I error.
The Bayesian ER design has better control of the type I error, which, however, is still inflated to over 20% in case D. Moreover, the expected sample size and duration are considerably larger than the frequentist counterpart in all null scenarios.
INSERT [15] , [16] ) that combines the response and time-to-event data in a mixture model. In this article we provide an alternative method based on conventional survival analysis (Cox PH models) and GLR hypothesis testing in an optimal group sequential design.
Our method does not require parametric modeling of the survival times, and uses a natural summary of the data to describe departures from the null treatment effect. It offers another option for investigators who would prefer a semiparametric approach, which is perhaps more familiar to consumers of trial information (including regulatory agencies). We note that the PH assumption in our model could (and should) be checked in existing databases of treatment trials of the same tumor type and similar drugs to the one being tested, if such data are available. Furthermore, we emphasize that our approach (and also the Bayesian approach) is based on the knowledge of a binary early outcome that is suitable for the go/no-go decision because it carries information on the distribution of time to event on the two treatment arms.
As measurement of response improves, one can expect that the relationship between response and clinical outcome will strengthen. In particular, the science underlying targeted therapies promises great strides toward the goal of early biological markers of long-term success or failure. Thus, the utility of response indicators should only increase in the future.
As they become more accurate, the value of modeling them with survival data in phase III trials will grow apace. The availability of mixture-based approaches, such as the Inoue-ThallBerry Bayesian approach and the standard semiparametric approach described in this article, may encourage investigators to take advantage of the response information. In addition, we hope that it will encourage a more coherent approach to therapeutic development. Instead of waiting for success in a randomized phase II trial before designing a definitive phase III trial, investigators can propose a definitive trial that stops early for futility. Funding, recruitment of sites, and other logistical issues can be addressed "just in time", as the interim milestones are achieved.
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The availability of statistical methods to support such trials may encourage funding agencies and sponsors to think more strategically about planning trials. One way to speed up the clinical development process is to eliminate or shorten the "stop and start" dead time between phase II and III. If investigators come to think that a randomized phase II-III trial that is progressing satisfactorily will likely be extended to its full size, they will be encouraged to begin randomizing earlier.
We anticipate that such changes will be forced on the field by the inefficiencies of the current development process, which is breaking down in the face of the throng of targeted therapies that clamor for clinical testing.
The proportional hazards model (4) can be readily extended to include covariates X i , or even more general time-varying covariates X i (t) to account for possible time variations in (4), as follows:
An important special case related to the emerging field of biomarker-guided personalized therapies is binary X i , taking the value 1 or 0 according to whether the ith patient belongs to the biomarker-positive subgroup or not. In this setting, π 0 and π 1 should be allowed to depend on X i , leading to four parameters π j,x (j = 0, 1; x = 0, 1). These extensions and their applications are presented elsewhere, but we want to point out here the ubiquity of the mixture survival model and the versatility of the methodology to handle it in Section 3. 
Therefore, as a → 1 and c → 1, the hazard ratio of treatment to control at every fixed t is (1)).
More generally, we can use Taylor's theorem to obtain that at every fixed t with S(t) > 0, (S(t)) a = e a log S(t) ≈ S(t) + (a − 1)(log S(t))S(t) as a → 1, and thereby generalize (A1) to
(1 − π 0 )S(t) + π 0 (S(t)) a ≈ S(t){1 − π 0 (1 − a) log S(t)} ≈ S(t)e −π 0 (1−a) log S(t) = (S(t)) π 0 a+1−π 0 as a → 1. Similarly, as ac → 1, we can generalize (A2) to
(1 − π 1 )(S(t)) b + π 1 (S(t)) abc ≈ (S(t)) b(π 1 ac+1−π 1 ) .
It then follows from (5) that at every fixed t with S(t) > 0, pr(T > t | Z = 1) = (S(t)) Survival curves for case E of Table 2 . Power and expected study duration of the three designs in Table 1 . 
